Rapt Therapeutics files for IPO at $75M Rapt Therapeutics, based in the US, filed to raise to $75 million in its IPO. This had come after five months when the company had retitled itself, which was...
HR-positive/HER2-negative breast cancer treatment landscape focuses on the complexity of the specific cancer type and the treatment differ according to the biomarker status. The trend suggests a greater bend towards personalized medicine based upon patient biomarkers and physiologic characteristics In our last a...
Find MoreBreast cancer is a serious and most common problem in developed as well as developing countries.About 1 in 8 U.S. women summing up to 12% are at the risk of developing invasive breast cancer over the course of her lifetime. And if we talk about the present scenario, there are over 3 million women in the United Stat...
Find MoreRoche’s Genentech has presented positive Phase III results from the IMvigor130 study aimed at studying Tecentriq (atezolizumab) tested in combination with platinum-based chemotherapy. The drug, Tecentriq, combined with Pt-based chemotherapy showed a noteworthy improvement in patients with untreated advanced bla...
Find MoreStipe Therapeutics (STipe) has raised USD 22 Million to move forward its clinical development of novel candidates to target intracellular protein-protein interactions of the STING Pathway. The financing round was led by Sunstone Life Science Ventures Fund IV, Novo Holdings, Arix Bioscience, and Wellington Partne...
Find MoreFlagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine. The launch of Omega therapeutics was planned to focus on epigenetic drugs to target diseases. Study of changes in gene expressions without any changes in the DNA sequence is known as Epigenetics. This oft...
Find MoreFUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...
Find MoreAlivaMab Discovery Services (ADS) has announced an antibody discovery agreement against multiple targets with Janssen Research & Developments. AlivaMab, a pharmaceutical providing fully human therapeutic antibody discovery services, will render its therapeutic antibody candidates, its clinical expertise and...
Find MoreMore than a dozen companies have shifted their focus towards the Hormone Receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer therapeutic area. Some of them are Jiangsu HengRui Medicine Co., Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche Group Syndax Ph...
Find MoreHormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast cancers. Hormone receptors are proteins that receive hormone signals and cue the cancer cells to grow. If breast cancer ce...
Find MoreSystemic Lupus Erythematosus (SLE) is a complex autoimmune disease that results in systemic inflamma.....
Find MoreThe medical device industry is experiencing rapid change as innovation is accelerating, new business.....
Find MoreCOVID-19 transforms healthcare facets at an unprecedented pace. Based on emerging technology, we can.....
Find MoreIntra-Tumoral Cancer Therapy refers to any therapy that is delivered in very close anatomical proxim.....
Find MoreIn the ATRT market domain, presently, there are a total of 11 drugs in the pipeline, which are in di.....
Find MoreMethicillin-resistant Staphylococcus aureus (MRSA) infection is caused by bacteria that have become .....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.